| Page 63 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Author(s): 
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.
Primary Author: 
Komrokji RS
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Mar 2019
BACKGROUND:
Bone Marrow Disease(s): 

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Author(s): 
Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, Garcia-Manero G.
Primary Author: 
Escalante CP
Journal Title: 
Cancer Med
Original Publication Date: 
Feb 2019
BACKGROUND:

Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia

Author(s): 
Xu ZL, Zhou M, Jia JS, Mo WJ, Zhang XH, Zhang YP, Wang Y, Li YM, Huang XJ, Wang SQ, Xu LP
Primary Author: 
Xu Zi
Journal Title: 
Bone Marrow Transplant
Original Publication Date: 
Jan 2019
Our study aimed to compare treatment outcomes between hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HID) and immunosuppressive therapy (IST) in adults with acquired severe
Bone Marrow Disease(s):